1. Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex

   • David J. Adams
   • Mateus Webba da Silva
   • Mansukh C. Wani

   Original Article 23 August 2005 Pages: 135 - 144

   

2. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient

   • David J. Adams
   • Miriam L. Wahl
   • Mansukh C. Wani

   Original Article 05 July 2005 Pages: 145 - 154

   

3. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

   • Sarah A. Holstein
   • Howard R. Knapp
   • Raymond J. Hohl

   Original Article 30 August 2005 Pages: 155 - 164

   

4. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells

   • Hideaki Nakazawa
   • Shuichi Yoshihara
   • Mutsuo Sasaki

   Original Article 15 September 2005 Pages: 165 - 170

   

5. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells

   • Olaf H. Temmink
   • Marco F. M. Hoogeland
   • Godefridus J. Peters

   Original Article 12 July 2005 Pages: 171 - 179

   

6. Thiolo-, thiono- and dithiocarbonate and thiocarbamate derivatives of demethylpenclomedine as novel anticancer agents

   • Robert F. Struck
   • William R. Waud

   Original Article 11 August 2005 Pages: 180 - 184

   

7. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

   • Vittorio Ferrari
   • Francesca Valcamonico
   • Giovanni Marini

   Original Article 03 September 2005 Pages: 185 - 190

   

8. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study

   • L. Nguyen
   • F. Leger
   • C. Puozzo

   Original Article 25 August 2005 Pages: 191 - 198

   

9. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study

   • Cheri E. Klein
   • Helen Kastrissios
   • Mark J. Ratain

   Original Article 13 September 2005 Pages: 199 - 206

   

10. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)

    • Christos Christodoulou
    • Haralambos P. Kalofonos
    • Epaminondas Samantas

    Original Article 19 July 2005 Pages: 207 - 212

    

11. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells

    • Jun Lee
    • Hui-Jun Zhou
    • Xiu-Hua Wu

    Original Article 02 August 2005 Pages: 213 - 220

    

12. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II

    • Brian B. Hasinoff
    • Xing Wu
    • Jack C. Yalowich

    Original Article 12 July 2005 Pages: 221 - 233

    

13. Expression of VDR and CYP24A1 mRNA in human tumors

    • Mark G. Anderson
    • Masaki Nakane
    • J. Ruth Wu-Wong

    Original Article 23 September 2005 Pages: 234 - 240

    

14. Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia

    • Jon D. Herrington
    • Hai T. Tran
    • Mark W. Riggs

    Original Article 25 August 2005 Pages: 241 - 247

15. Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL)

    • Rong Lu
    • Jing Jia
    • Zhi Yao

    Original Article 19 July 2005 Pages: 248 - 256

    

16. Analysis of cytotoxicities of platinum compounds

    • Jerry Goodisman
    • Douglas Hagrman
    • Abdul-Kader Souid

    Original Article 19 July 2005 Pages: 257 - 267

    

17. Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo

    • Bo Yang
    • Qiao-jun He
    • Rui-ying Fang

    Original Article 23 August 2005 Pages: 268 - 273